AEON AEON Biopharma Inc. - Ordinary Shares - Class A

$AEON Lake Street raised the firm’s on Biopharma (AEON) to $2 from $1 and keeps a Buy rating on the shares after the company announced the outcome of its Type 2b meeting with FDA.

$AEON needs to stay above .25 watching closely $QCLS patiently waiting for the boom $CNTB stay above a dollar, and could see another pump! $SOAR patiently waiting here too

$AEON Share price went up to 41.8 almost 42 cents today and then totally crashed. Cashless warrants totally destroyed the high share price gain earlier today.

$AEON The biggest positive from today's announcement is regulatory clarity, rather than approval itself. FDA hasn't blocked the 351(k) biosimilar strategy; it has agreed in principle to AEON's CMAP approach, allowed AEON to potentially leverage substantial existing human data, and AEON can now move forward toward the next FDA interaction. I expect more to come from the company soon! This could fast track things

$AEON i have not been following too closely but i do like there regulatory guy. very rare to find a reg guy that worked at the FDA. if this thing tanks again its almost worth buying in

$AEON sold long ago and back after a leave of absence. seems like an RS is a ways off. could be good to get back in

$AEON i’m right there with you TW I’m very bullish on this stock, but the numbers are the numbers they’re gonna have to raise money before they start playing these FDA games. I think the market knows this and the market also possibly sees a reverse split.

$AEON On the hourly chart, a double bottom and a falling wedge appear to be in progress, with potential targets around $0.48 and $0.60, respectively, if validated (not advice, just patterns and probabilities)

$AEON AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

$AEON is active on FDA approval following a Globe Newswire release. AEON Biopharma received FDA feedback supporting a streamlined biosimilar development pathway for ABP-450, with IND submission planned for Q4 2026. RTPR pushed this release out to users at 8:00:01 AM ET

$AEON i always find it fascinating how few take some time to research. it looks like they are voting on an RS

$AEON Disappointed doesn't begin to describe my thoughts on this stock. The company likely just saved $30M and almost a year by not needing a comparative study. The molecule is so well studied that they can innundate the FDA with data. Approval seems highly likely and this will take a ton of share due to better economics. I was so excited to buy it here on Wednesday. Thought it would never trade here again. I guess the moral to the story is that all micro-cap biotechs are trading vehicles not investments?!? Dang...

$AEON The $.32 warrants are not cashless My guess is stock trades through there soon and they get exercised. Funds them for a nice while. The value here, if they don’t need a comparative study is excellent.

$AEON Yesterday's milestone news may significantly outweigh the potential warrant exercise. One can ask an LLM to calculate a probabilistic distribution of discounted future cash flows and corresponding market capitalization based on the recently reached milestone by factoring in prospective annual revenues (subject to assumptions such as subsequent approvals and successful commercialization), current financials, expected proceeds from the exercise of warrants, estimates for the total number of eventual outstanding shares, additional funding needs until final approval (if the success criteria for the next trials are met as well and approval is granted), and commercialization, as well as other relevant parameters. Even in conservative scenarios with weighted probabilities, the current stock price may turn out to be notably undervalued. (Not advice, just inferences from an LLM-supported examination, dyodd)

$AEON but remember warrants have Nov 16 expiration date, so greedy holders need to let it go for bigger money

$AEON $AEON 🔥 This one is getting interesting. ABP-450 continues to show strong biosimilarity to BOTOX, with recent testing showing comparable potency degradation and oxidation patterns. Previous structural analysis showed 100% amino-acid sequence identity across analyzed regions with ~98% sequence coverage. FDA feedback has supported AEON’s 351(k) biosimilar development strategy, and the company brought in former FDA neuroscience leader Paul Lee to strengthen regulatory execution. If the next FDA feedback further clears the development path, $AEON could have a serious catalyst ahead. 👀🔥

$AEON very hard anytime FDA approve of any clinical continuing advancement. This stock heading towards high pps, indeed.

$AEON is quietly moving higher, don't tell anybody. Meanwhile it is easy to understand why an insider recently meaning a few weeks ago bought more than 1 million shares. Look it up.

$AEON is very bullish now on every chart. I'm holding for above 1 dollar per share and higher. I can wait weeks or months makes no difference to me. Just a hint of a buyout or a partnership deal would move the share price a lot higher.

$AEON chart looking primed! Slow and steady. News will rock this! Buyout? If I was Botox, I'd be considering buying this company out.